# Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer

> **NCT02207335** · PHASE3 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Gemcitabine，Capecitabine
- **DRUG:** Gemcitabine, Carboplatin

## Key facts

- **NCT ID:** NCT02207335
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207335, "Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02207335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*